Fish Oils (Omega 3) in ischaemic stroke
Phase 2
Completed
- Conditions
- Ischaemic Cerebrovascular DiseaseIschaemic Cerebrovascular StrokeStroke - Ischaemic
- Registration Number
- ACTRN12605000207617
- Lead Sponsor
- Health Research Council (New Zealand)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 220
Inclusion Criteria
1. CT confirmed first-ever or recurrent ischaemic stroke 2. Clinically stable with atheromatous disease history greater than 3 months.
Exclusion Criteria
1. Known intolerance or hypersensitivity to fish and /or fish oils. 2. Current use of fish oils (dietary supplements) 3. Known to be pregnant or breast feeding 4. Active disease causing malabsorption.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To evaluate the effectiveness of Omega-3 PUFAs in improving lipid profiles[At 12 weeks]
- Secondary Outcome Measures
Name Time Method To evaluate the treatment on changes in weight, blood pressure, inflammatory and haemostatic markers of cardiovascular disease, and mood.[ The study will provide efficacy and tolerability data on the study treatment given for a total of 12 weeks. ];Lipid profile (TC, LDL-C, HDL-C, TG [primary]; LDL-particle size, Apo B), inflammatory markers (hsC-RP, LFT, FBC, ESR, ferritin), haemostatic clotting (fibrinogen), blood pressure, body mass index (BMI), body weight, waist to hip ratio, mood (GHQ 28-item general health questionnaire) and health-related quality of life (SF-36 item short form questionnaire).[Will be collected at baseline and 12 weeks.]